INTRODUCTION {#SEC1}
============

Developing an efficient gene editing tool is crucial for the development of vaccines against pathogenic bacteria, the promotion of beneficial products for probiotic microorganisms and industrial microbiology ([@B1]), and gene-function studies in bacteria ([@B4]). During recent years, a few bacterial gene editing tools have been developed. These generally include the following three types: (i) random integration mediated by transposons ([@B5]); (ii) the site-specific recombination based on the integrase family and the resolvase/invertase family, which rely on specific sequences in the bacterial genome ([@B6],[@B7]) and (iii) bacterial homologous recombination systems, which can concisely manipulate the bacterial genome. However, the efficiency of homologous recombination is low in its natural condition ([@B8],[@B9]). How to obtain the mutant at a high efficiency is an essential issue. To overcome such obstacles, two strategies have been developed ([@B10]). One strategy is a negative selection system that is based on the killing of non-mutant strains for the isolation of mutant strains, which includes antibiotic selection systems, SacB selection system ([@B11]), galk selection system ([@B12]), thermo-sensitive system ([@B13]), thymidylate synthase A selection system ([@B14]), Toxin-Antitoxin Cassette ([@B15]), and Restriction-Modification System ([@B16]). Actually, this strategy has also been used by the newly developed clustered, regularly interspaced, short palindromic repeats (CRISPR)--associated Cas9 system for bacterial engineering ([@B1],[@B17]). The CRISPR-Cas9 system relies on guide RNA (gRNA):Cas9-directed cleavage at a targeted genomic site to kill unmutated cells and circumvents the need for selectable markers or counter-selection systems ([@B18]). The other strategy is a positive selection system that depends on the promotion efficiency of homologous recombination, which includes the introduction of recombinase A (recA) ([@B20],[@B21]), a key enzyme involved in the DNA recombination and repair ([@B22]). Although the introduction of recA could significantly promote the efficiency, the recombination efficacy was still quite low ([@B21]).

*Pasteurella multocida* is a gram-negative coccobacillus that infects various hosts and leads to huge economic losses in the poultry, cattle and saiga antelopes industries ([@B23],[@B24]). It is also the most common causative organism isolated from dog-bite or cat-bite wounds ([@B25]). Additionally, the isolation of a few higher virulent and multiple antibiotic-resistant strains has made the development of novel vaccines and pathogenesis studies more urgent ([@B26]). Although a thermo-sensitive system was developed for gene manipulation in *P. multocida* NADC TT94 ([@B13]), it worked at a low efficiency in the highly virulent and multiple antibiotic-resistant strain GX-PM ([@B26]). We further attempted various methods for gene editing, such as the galk selection system, the thymidylate synthase A selection system, and the SacB system, but all failed. Therefore, finding a new, highly safe and efficient system for robust gene editing is of high priority.

Argonaute proteins (Agos) were initially discovered in eukaryotes as key proteins in RNA interference systems ([@B27]). Both eukaryotic Agos and long prokaryotic Agos (pAgos) form a bi-lobed scaffold, in which one lobe consists of the amino-terminal (N) and PIWI--Argonaute--Zwille (PAZ) domains, whereas the other lobe consists of the middle (MID) and PIWI domains ([@B28]). The MID and PAZ domains usually form binding pockets that facilitate the anchoring of the 5′ and 3′ ends of an oligonucleotide guide, respectively ([@B30]). On target binding, the PIWI domain of catalytically active Agos (that contain the DEDX motif, in which X denotes D, H or N ([@B31])) mediates cleavage of cognate DNA targets ([@B31]) or RNA targets *in vitro* ([@B32],[@B35]). These suggest a potential for prokaryotic Argonaute proteins as a novel gene-editing tool ([@B30]). Recently, DNA-guided genome editing with *Natronobacterium gregoryi* Argonaute (*Ng*Ago) has been developed for genome editing in eukaryotic cells, but the original report was retracted due to the continued inability of the research community to replicate the key findings ([@B36],[@B37]). Interestingly, *Ng*Ago was identified as a genetic tool for gene silencing in zebrafish ([@B38]) or for degradation of pregenomic RNA during Hepatitis B virus infection ([@B39]). However, no study reports its potential role in bacterial gene editing. Here, we present the successful genetic manipulation of a few bacterial isogenic mutants with the *Ng*Ago and other pAgos fragments systems, demonstrating its potential role in bacterial gene editing as an effective positive selection system independent of its potential enzyme activity.

MATERIALS AND METHODS {#SEC2}
=====================

Bacterial strains, plasmids and DNA oligos {#SEC2-1}
------------------------------------------

The bacterial strains and plasmids used in this study are presented in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. The Primers for PCR are presented in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. The guide DNA (gDNA) sequences for target genes are presented in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}.

Construction of pSHK5(TS)-*Ng*Ago {#SEC2-2}
---------------------------------

A *Ng*Ago gene (GenBank ID: [KU899087.1](KU899087.1)) was amplified by PCR with the *Ng*Ago-L/R primers and a High-Fidelity DNA polymerase (NEB). A ribosome binding sequence (rbs) was amplified by PCR from the avian *P. multocida* strain GX-PM genome with the RBS-L/R primers ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The *Ng*Ago gene and rbs were connected by fusion PCR with the RBS-RH-L/*Ng*Ago-RH-R primers, and then inserted upstream of the kanamycin resistance gene (kan^r^) in the temperature-sensitive *P. multocida*--*E. coli* shuttle vector pSHK5(TS) to generate the pSHK5(TS)-*Ng*Ago plasmid with the pSHK5(TS)-RBS-RH-F/pSHK5(TS)-*Ng*Ago-RH-R and *Ng*Ago-Kan-RH-F/R primers.

Next-generation sequencing of the bacterial genome {#SEC2-3}
--------------------------------------------------

*Pasteurella multocida* strains (GX-PM and the constructed isogenic *lyi* gene mutants with or without gDNA) were sequenced at the Shanghai Sangon Biotech using Illumina technology. For all bacteria genomes, we constructed and sequenced an Illumina short-insert paired-end library. The majority of the genomes were assembled using the ALLPATHS and Velvet assembly methods.

Pull-down assay coupled with LC-MS/MS {#SEC2-4}
-------------------------------------

An *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag, pSHK5(TS)-*Ng*Ago fragments (A, B or D)-Flag, or pSHK5(TS). The bacteria were collected in 2 ml RIPA buffer (Beyotime), and then lysed by two passages through a French pressure cell (Thermo, USA) at 20 000 lb/in.^2^. After centrifugation at 12 000g for 10 min, the supernatants were collected and further purified with FLAG M Purification Kit (Sigma-Aldrich, CELLMM2). Finally, the interacting proteins were recovered with PBS buffer containing 300 μg/ml of 3× FLAG peptides (Sigma-Aldrich, F4799). The eluted proteins were subjected for analysis by LC-MS/MS with Eksigent nanoLC-Ultra 2D (AB SCIEX) and TripleTOF 5600 (AB SCIEX). The data analysis was performed with the Mascot 2.3 (Matrix Science) and was based on the SwissProt 57.15 database (Taxonomy: *E. coli*) with the following parameters: Type of search: MS/MS Ion Search; Mass values: Monoisotopic; Fixed modifications: Carbamidomethyl (C); Variable modifications: Acetyl (Protein N-term), Deamidated (NQ), Dioxidation (W) and Oxidation (M); Peptide mass tolerance: ±30 ppm; Fragment mass tolerance: ±0.15 Da; and Max missed cleavages: 2. To ensure the reliability of identified proteins, proteins that more than two unique peptides were successfully matched were recognized as the identified proteins.

Analysis of the interaction of *Ng*Ago and recA {#SEC2-5}
-----------------------------------------------

An *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL (the left arm sequences of aste gene), pSHK5(TS)-asteL, pSHK5(TS)-*Ng*Ago-Flag or pSHK5(TS). The bacteria were lysed by two passages through a French pressure cell (Thermo, USA) at 20 000 lb/in.^2^, and the proteins were collected for analysis with FLAG M Purification Kit (Sigma-Aldrich, CELLMM2). The eluted proteins were collected in 100 μl of TE buffer containing 1% SDS and then were subjected for immunoblot analysis with rabbit polyclonal antibodies against recA (Abcam, ab63797) or rabbit polyclonal antibodies against Bacteriophage phic31 integrase (Abcam, ab93248). Images were obtained on the MF Chem BIS Bio-Imaging System (DNR). All experiments were completed in triplicate. This assay was also performed to detect the interaction between the recA and *Ng*Ago fragments (A, B, D, E and F), *Pyrococcus furiosus* Argonaute fragment D (*Pf*Ago-D, 316--771 aa, containing MID and PIWI domains), *Thermus thermophilus* Argonaute fragment D (*Tt*Ago-D, 316--685 aa, containing MID and PIWI domains), or *Aquifex aeolicus* Argonaute fragment D (*Aa*Ago-D, 314--706 aa, containing MID and PIWI domains).

An *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL, pSHK5(TS)-asteL, pSHK5(TS)-*Ng*Ago-Flag or pSHK5(TS). Proteins were extracted for analysis with 50 μl Protein A agarose (KPL) with or without 5 μl rabbit polyclonal antibodies against recA (Abcam) and incubated for 3 h at 4°C. To confirm the identification of the recA-interacting proteins, the purified proteins were further subjected for immunoblot analysis with rabbit polyclonal antibodies against recA (Abcam, ab63797) and peroxidase-labelled goat anti-rabbit IgG(H+L) (KPL) or anti-DDDDK-Tag FLA-1 purified IgG/Mouse (MBL) and peroxidase-labeled goat anti-mouse IgG(H+L) (KPL), followed by development with the clarity™ western ECL Substrate (Bio-Rad). This assay was also performed to detect the interactions between the *Ng*Ago fragments (A, B, D, E and F) and recA.

The interaction of recA and NgAgo in the presence of **Dnase I** {#SEC2-6}
----------------------------------------------------------------

An *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL, pSHK5(TS)-asteL, pSHK5(TS)-*Ng*Ago-Flag or pSHK5(TS). The total proteins were extracted as described before and then digested with or without 8 μl Dnase I (10g/ml, Sangon Biotech) at 37°C for 3 h. Subsequently, these proteins were subjected for analysis with FLAG M Purification Kit (Sigma-Aldrich, CELLMM2). The eluted protein were collected in 100 μl of TE buffer containing 1% SDS and then were subjected for immunoblot analysis with rabbit polyclonal antibodies against recA (Abcam, ab63797) and peroxidase-labelled goat anti-rabbit IgG(H+L) (KPL) or anti-DDDDK-Tag FLA-1 purified IgG/Mouse (MBL) and peroxidase-labeled goat anti-mouse IgG(H+L) (KPL), Images were obtained on the MF Chem BIS Bio-Imaging System (DNR). All experiments were completed in triplicate.

Recombinant expression and purification of *Ng*Ago and recA from *E. coli* and *P. multocida* {#SEC2-7}
---------------------------------------------------------------------------------------------

The *Ng*Ago gene was amplified with primers *Ng*Ago-pET28a-RH-F/R or Flag-pET28a-*Ng*Ago-RH-F/R (Table S2). Then both PCR fragments were cloned into the prokaryotic expression vector pET28a. The recombinant *Ng*Ago-His (r*Ng*Ago-His) and *Ng*Ago-FLAG (r*Ng*Ago-FLAG) was expressed in *E. coli* (BL21), and purified with Ni-NTA agarose (GE Healthcare) or ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich) according to the manufacturer\'s instructions.

The ErecA or PmrecA gene was amplified from *E. coli* genome or *P. multocida* GX-PM genome with primers ErecA-pET28a-RH-F/R or PmrecA-pET28a-RH-F/R. Both PCR fragments were cloned into the prokaryotic expression vector pET28a, and then transformed into *E. coli* (BL21) for expression. Either recombinant ErecA (rErecA) or PmrecA (rPmrecA) was purified with Ni-NTA agarose (GE Healthcare) according to the manufacturer\'s instructions.

Analysis of the direct interaction of *Ng*Ago and recA {#SEC2-8}
------------------------------------------------------

The purified r*Ng*Ago-FLAG and the rErecA or rPmrecA were incubated for 3 h at 4°C. Then the proteins were subjected for co-purification with Ni-NTA agarose (GE Healthcare) or ANTI-FLAG M2 Affinity Gel. The eluted proteins were further subjected for immunoblot analysis with rabbit polyclonal antibodies against recA (Abcam, ab63797) and peroxidase-labelled goat anti-rabbit IgG(H+L) (KPL) or anti-DDDDK-Tag FLA-1 purified IgG/Mouse (MBL) and peroxidase-labelled goat anti-mouse IgG(H+L) (KPL), followed by development with the clarity™ western ECL Substrate (BIO-RAD).

Binding studied by surface plasmon resonance (SPR) {#SEC2-9}
--------------------------------------------------

The binding of recA to *Ng*Ago under laminar flow was analyzed by SPR using a BIAcore T200 system (GE Healthcare). The surface of a carboxymethylated dextran (CM5) sensor chip (GE Healthcare) was activated with 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 0.1 M N-hydroxysuccinimide. r*Ng*Ago-His was immobilized by amine coupling to one flow cell. All free reactive surface groups were blocked using 1 M ethanolamine. BSA was immobilized onto the other flow cell as nonspecific binding control. Different concentrations (0--4 μM) of rErecA in PBS buffer containing 0.5% Tween-20 were injected over the flow cells at 60 μL/min (contact time, 2 min). After each injection, any bound protein was stripped with 6.25 mM NaOH (15 s). Data analysis was performed using the BIAcore T200 evaluation software 3.1 (GE Healthcare), which allowed determination of Ka, Kd, and KD values by fitting the derived sensograms to 1:1 Langmuir model. A separate determination of the equilibrium constant KD was performed to validate curve fitting by plotting the maximal responses (RUmax) against substrate concentration and fitting to one-binding site model. The binding of r*Ng*Ago-His to rErecA was also performed similarly. rErecA and BSA were immobilized by amine coupling to each flow cell, and different concentrations (0--2.5 μM) of r*Ng*Ago-His in PBS buffer containing 0.5% Tween-20 was injected over the flow cells for analysis.

Chromatin immunoprecipitation (ChIP)-qPCR {#SEC2-10}
-----------------------------------------

*E. coli* was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL or pSHK5(TS)-asteL ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) and cultured in 10 ml LB medium for 12 hours. Then the bacteria were cross-linked for 1 h with formaldehyde at a 1% final concentration (Sigma-Aldrich) and quenched by the addition of glycine to 125 mM for 10 min. The bacterial pellets were resuspended in 2 ml RIPA buffer (Beyotime) with 50 μl lysozyme (100 mg/ml, Sangon Biotech) and incubated at 37°C for 30 min. The samples were chilled and sonicated for 5 min in a Uibra cell TM Sonics (500W, Shanghai SpringSci Co., Ltd) with 9 s on/9 s off pulsing at 40% amplitude. After centrifugation at 12 000g for 10 min, 100 μl of supernatants were collected as input controls for qPCR. The other supernatants were incubated with 50 μl Protein A agarose beads (KPL) with 5 μl rabbit polyclonal antibodies against recA (Abcam) for 2 h at 4°C. The agarose beads were resuspended in 100 μl of elution buffer as ChIP samples. Next, 4 μl of 500 mM NaCl was added into the prepared samples, including the ChIP samples and input controls, and then incubated at 65°C for 8 h to reverse the DNA--protein crosslinking. Then, all the samples were purified by using a PCR purification kit (Qiagen). The FastStart Universal SYBR^R^ Green master (ROX) (Roche) was applied for qPCR according to the manufacturer\'s instructions ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Electrophoretic mobility shift (EMSA) assay {#SEC2-11}
-------------------------------------------

Reactions contained Tris--HCI (70 mM, pH 7.6), MgCl~2~ (10 mM), dithiothreitol (5 mM), ATP-γS (2.0 mM), rErecA (variable concentrations), and phiX174-oligo chemically labeled with Cy5 (125 nM) were combined to a final volume of 20 μl and incubated at 37°C for 60 min to form recA-ssDNA filaments in the presence of various concentration of r*Ng*Ago-His. The reaction products were resolved on a 1% agarose gel and imaged on a Fujifilm FLA-5100 (FUJIFILM Life Science, Japan).

DNA Strand exchange assay {#SEC2-12}
-------------------------

A reaction mixture containing Tris--HCl (70 mM, pH 7.6), MgCl~2~ (10 mM), dithiothreitol (5 mM), ATP-γS (2.0 mM), rErecA (variable concentrations), HPLC-purified phiX174-oligo chemically labeled with Cy5 (125 nM), was incubated at 37°C for 10 min to form recA-ssDNA filaments. D loop formation was initiated with the addition of 1 μg phiX174 RF1 DNA and various concentration of r*Ng*Ago-His to the mixture, and incubated at 37°C. The reaction was stopped via addition of Proteinase K and 1% SDS at room temperature. Reaction products were resolved on a 1% agarose gel and imaged on a Fujifilm FLA-5100 (FUJIFILM Life Science, Japan).

RESULTS {#SEC3}
=======

*Ng*Ago-assisted gene editing in *P. multocida* {#SEC3-1}
-----------------------------------------------

An *Ng*Ago gene was inserted upstream of the kanamycin resistance gene (kan^r^) in the temperature-sensitive *P. multocida*--*E. coli* shuttle vector pSHK5(TS) to generate the pSHK5(TS)--*Ng*Ago plasmid (Figure [1A](#F1){ref-type="fig"}, [Supplementary Table S1-2](#sup1){ref-type="supplementary-material"}). The homologous arms of the target gene, e.g. the *lyi* (lysozyme inhibitor) gene, were inserted into the pSHK5(TS) or pSHK5(TS)-*Ng*Ago plasmid to yield pSHK5(TS)-lyiLR or pSHK5(TS)-*Ng*Ago-lyiLR, respectively. To test whether *Ng*Ago could promote gene editing, either the pSHK5(TS)-lyiLR plasmid or pSHK5(TS)-*Ng*Ago-lyiLR plasmid with guide-DNA (gDNA) were electro-transformed into the *P. multocida* strain GX-PM (Figure [1A](#F1){ref-type="fig"}, [Supplementary Table S1 and S3](#sup1){ref-type="supplementary-material"}). As a result, isogenic mutants could only be detected at 100% efficiency with the *Ng*Ago system by PCR with the lyi-ID1F/R primers (Figure [1B](#F1){ref-type="fig"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}), indicating that the efficiency of natural homologous recombination in the *P. multocida* strain is negligible, while the *Ng*Ago system is robust for gene editing in *P. multocida* without off-target effect which was confirmed by next-generation sequencing (Figure [1C](#F1){ref-type="fig"}).

![*Ng*Ago-assisted gene editing in *P. multocida* and *E. coli*. (**A**) Schematic construction of the isogenic *lyi* (lysozyme inhibitor) gene mutant for *P. multocida*. An *Ng*Ago gene with a ribosome binding sequence (rbs) was introduced upstream of the kanamycin resistance gene (kan^r^) in the temperature-sensitive *P. multocida-E. coli* shuttle vector pSHK5(TS) to generate the pSHK5(TS)-*Ng*Ago plasmid. The homologous arms of the *lyi* gene were then inserted into the pSHK5(TS) or pSHK5(TS)-*Ng*Ago plasmid to yield pSHK5(TS)-lyiLR or pSHK5(TS)-*Ng*Ago-lyiLR, respectively. Subsequently, the two plasmids were electro-transformed into the *P. multocida* strain GX-PM with guide DNA (gDNA) to isolate the isogenic mutants by PCR with the lyi-ID1F/R primers. (**B**) Construction efficiency of the avian *P. multocida* strain GX-PM with deletion of the *lyi, opa* (Opacity-associated protein), *pilia* (type IV fimbrial subunit protein), *fhgb* (Flavohemoglobin), *hfq* (RNA chaperone Hfq), or *hyae* (hydrogenase-1 operon protein) gene with or without *Ng*Ago system. (**C**) Representatives of whole genome sequencing for the *P. multocida* strain GX-PM with the deletion of the *lyi* gene with or without gDNA. (**D**) Comparison of the virulence of the avian *P. multocida* strain GX-PM with the constructed isogenic *hyae* mutant in chickens. Infection of chickens with the avian *P. multocida* strain GX-PM caused mortality of 100% in the third day of post-infection, while infection of the constructed isogenic *hyae* mutant could not cause any death during the trial (*n* = 5). (**E**) Severe damage to several vital organs in response to infection with the avian *P. multocida* strain GX-PM was not observed in the chickens infected with the constructed isogenic *hyae* mutant. (**F**) Construction efficiency of the rabbit *P. multocida* strain C51-17 with deletion of the *opa* (Opacity-associated protein) gene or insertion of a *vp60* gene from *rabbit haemorrhagic disease virus*; and the *E. coli* strain with the *aste* (succinylglutamate desuccinylase) gene deletion with or without *Ng*Ago system.](gkz040fig1){#F1}

To test whether the *Ng*Ago-based gene knockout in *P. multocida* is successful only for a *lyi* gene, we applied this approach to manipulate several additional genes. As shown in Figure [1B](#F1){ref-type="fig"} and [Supplementary Figure S2-S6](#sup1){ref-type="supplementary-material"}, *opa* (Opacity-associated protein), *pilia* (type IV fimbrial subunit protein), *fhgb* (Flavohemoglobin), *hfq* (RNA chaperone Hfq), and *hyae* (hydrogenase-1 operon protein) genes, were successfully removed from the genome with phenotype efficiencies of 95%, 80%, 85%, 95% and 90%, respectively. The virulence of the constructed isogenic *hyae* mutant in chickens was significant decreased compared with the *wt* strain GX-PM, which caused high mortality and severe damage to several vital organs ([@B26]), e.g., liver, heart and duodenum (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}), indicating that the *Ng*Ago system could help successfully delete the genes in *P. multocida* at a high efficiency.

*Ng*Ago-assisted gene editing in *E. coli* and rabbit *P. multocida* strain {#SEC3-2}
---------------------------------------------------------------------------

To further test whether the *Ng*Ago-based system is bacterial strain-specific, we applied it to the rabbit *P. multocida* strain C51-17 and *E. coli*. As shown in Figure [1F](#F1){ref-type="fig"} and [Supplementary Figure S7-S8](#sup1){ref-type="supplementary-material"}, both representative genes *opa* and *aste* (succinylglutamate desuccinylase) were completely removed from the genome of the C51-17 strain and *E. coli*, respectively, at an efficiency of 100%. Additionally, *Ng*Ago-based specific gene (a *vp60* gene from *rabbit haemorrhagic disease virus*) knock-in editing is also possible, as shown in Figure [1F](#F1){ref-type="fig"} and [Supplementary Figure S9](#sup1){ref-type="supplementary-material"}. These data suggest that the *Ng*Ago system is potentially efficient for bacterial gene editing.

*Ng*Ago-assisted gene editing is based on the homologous sequences and is independent of its potential enzymatic activity and gDNA {#SEC3-3}
----------------------------------------------------------------------------------------------------------------------------------

In terms of the high efficiency of *Ng*Ago-based gene editing in bacteria, we aimed to determine the crucial role of *Ng*Ago in bacterial homologous recombination. As both eukaryotic and prokaryotic Agos have conserved DEDX motif with confirmed or predicted catalytic activity ([Supplementary Figures S10 and S11](#sup1){ref-type="supplementary-material"}), we introduced single or double mutations for Asp663 and Asp738 in *Ng*Ago, obtaining *Ng*Ago-D663A and *Ng*Ago-D663A-D738A ([Supplementary Table S1-S2](#sup1){ref-type="supplementary-material"}), which are predicted to inhibit the potential catalytic activity of *Ng*Ago ([@B38],[@B40]). We found that transformation of each pSHK5(TS)-*Ng*Ago-lyiLR mutant vector efficiently caused *lyi* knockout, with phenotype efficiencies of 100% and 90% (Figure [2A](#F2){ref-type="fig"} and [Supplementary Figure S12](#sup1){ref-type="supplementary-material"}). This indicates that the *Ng*Ago system enhances homologous sequence-guided gene editing in bacteria independent of its potential enzyme activity. Additionally, this was further supported by the finding that no insertion/deletion mutations were detected in the bacterium transformed with gDNA/*Ng*Ago using a T7E1 enzyme assay ([Supplementary Figure S13](#sup1){ref-type="supplementary-material"}). These results seem to conflict with our previous attempt to use the *Ng*Ago/guide complex to cleave the target sequences of genome for counter-selection. Surprisingly, gDNA is not required in the bacteria as long as the homologous arms are present (Figure [2B](#F2){ref-type="fig"} and [Supplementary Figure S14](#sup1){ref-type="supplementary-material"}). Thus, we hypothesized that the homologous arms are required for *Ng*Ago-mediated gene editing in bacteria, while both the potential enzyme activity and gDNA are not necessary.

![*Ng*Ago-assisted gene editing independent of its potential enzymatic activity and guide DNA (gDNA). (**A**) Construction efficiency of isogenic *lyi* mutant in the *P. multocida* strain GX-PM based on *Ng*Ago or the *Ng*Ago mutants *Ng*Ago-D663A and *Ng*Ago- D663A-D738A, which are predicted to lack *Ng*Ago potential catalytic activity. (**B**) Comparison of the construction efficiency of the isogenic *lyi* mutant in the *P. multocida* strain GX-PM based on *Ng*Ago with or without gDNA. (**C**) Construction of isogenic *lyi* mutant in the *P. multocida* strain GX-PM with pSHK5(TS)-*Ng*Ago-lyiLR, which was further inserted with other homologous sequences (opaL) or non-homologous sequences (*gfp* gene sequence).](gkz040fig2){#F2}

Because the homologous arms were enough for *Ng*Ago-assisted gene editing, we further tested whether other homologous sequences had an inhibitory effect of target gene deletion. Indeed, we observed that the phenotype based on the bacterial *Ng*Ago system was significantly disturbed when additional homologous sequences (*opal* sequence) are introduced (Figure [2C](#F2){ref-type="fig"} and [Supplementary Figure S15](#sup1){ref-type="supplementary-material"}). In contrast, an exogenous non-homologous sequence (*gfp* sequence) could not interfere with the construction of an isogenic *lyi* mutant based on the *Ng*Ago system (Figure [2C](#F2){ref-type="fig"} and [Supplementary Figure S15](#sup1){ref-type="supplementary-material"}). This result further suggested that *Ng*Ago-assisted gene editing is based on homologous sequence-directed recombination.

*Ng*Ago-assisted gene editing through binding to recA {#SEC3-4}
-----------------------------------------------------

To elucidate the mechanism underlying *Ng*Ago-assisted genetic manipulation, we used pull-down approaches coupled with LC-MS/MS to identify *Ng*Ago-interacting proteins. Interestingly, homologous recombinase recA, an essential protein in bacterial homologous recombination and genome DNA repair ([@B22]), was identified as the dominant *Ng*Ago-interacting protein ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). This specific interaction between *Ng*Ago and recA was further validated by Co-IP approaches (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}), and phiC31 integrase as a control exhibited no interaction with *Ng*Ago ([Supplementary Figure S16](#sup1){ref-type="supplementary-material"}). Furthermore, the interaction of *Ng*Ago and recA was not significantly blocked in the presence of Dnase I ([Supplementary Figure S17](#sup1){ref-type="supplementary-material"}), indicating that the interaction was not mainly through binding to DNA.

![*Ng*Ago interacts with recA and enhances recA-mediated DNA strand exchange in bacteria. (**A**) Co-IP assay detection of the interaction between *Ng*Ago-FLAG and endogenous recA with αFLAG agarose. The *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL (the left arm sequences of aste gene), pSHK5(TS)-asteL, pSHK5(TS)-*Ng*Ago-Flag or pSHK5(TS) and cultured for 48 hours. Total proteins were extracted for Co-IP assay with αFLAG agarose. (**B**) Co-IP assay detection of the interaction between *Ng*Ago-FLAG and endogenous recA with SPA/G agarose and αrecA. The *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL, pSHK5(TS)-asteL, pSHK5(TS)-*Ng*Ago-Flag or pSHK5(TS) and cultured for 48 h. Total proteins were extracted for Co-IP assay with SPA/G agarose and αrecA. (**C**) Direct interaction between the purified recombinant *Ng*Ago-FLAG with the purified recombinant ErecA-His with αFLAG agarose. The eluted proteins were further subject for immunoblot with antibodies against recA or FLAG. (**D**) Direct interaction between the purified recombinant *Ng*Ago-FLAG with the purified recombinant ErecA-His with Ni-NTA agarose. The eluted proteins were further subject for immunoblot with antibodies against recA or FLAG. (**E**) The curves representing the binding of purified rErecA-His to r*Ng*Ago-His. r*Ng*Ago-His and BSA were immobilized by amine coupling to each flow cell, and different concentrations (0-4 μM) of rErecA was injected over the flow cells for surface plasmon resonance analysis. Data were obtained as response value of rErecA-His to r*Ng*Ago-His subtracting response value of rErecA-His to BSA. (**F**) The plotting of the RUmax at each concentration of rErecA for r*Ng*Ago-His. These curves were fitted to the one-binding site model, giving values for KD constants. (**G**) The curves representing the binding of purified r*Ng*Ago-His to rErecA-His. rErecA-His and BSA were immobilized by amine coupling to each flow cell, and different concentrations (0--2.5 μM) of r*Ng*Ago-His was injected over the flow cells for surface plasmon resonance analysis. Data were obtained as response value of r*Ng*Ago-His to rErecA-His subtracting response value of r*Ng*Ago-His to BSA. (**H**) The plotting of the RUmax at each concentration of r*Ng*Ago-His for rErecA. These curve was fitted to the one-binding site model, giving values for KD constants. (**I**) Enhanced binding of recA with the target DNA by *Ng*Ago. The *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago-Flag-asteL or pSHK5(TS)-asteL and cultured for 12 h, then cross-linked with formaldehyde. After sonication, the lysate was precipitated with SPA agarose and αrecA. After reverse crosslinking the samples, the samples were used for qPCR detection of asteL with the aste-RT-F/R primers or the irrespective *gapa* sequence with the gapa-RT-F/R primers. The *reca* sequence was used as an internal control for qPCR with the reca-RT-F/R primers. (**J**) *Ng*Ago-assisted gene editing is through enhancing recA-mediated DNA strand exchange. DNA strand exchange assay was performed based on the phiX174 RF1 DNA and HPLC-purified phiX174-oligo chemically labeled with Cy5 in the presence of rErecA and various concentration of r*Ng*Ago-His. The products were resolved on a 1% agarose gel, and the D-loop formation and free of Cy5-labeled oligos were imaged on a Fujifilm FLA-5100 (FUJIFILM Life Science, Japan). The D-loop formation % is the percentage of the signal of the D-loop formation of Cy5-labed oligos in the signal of the D-loop formation and free of Cy5-labeled oligos.](gkz040fig3){#F3}

Moreover, the purified r*Ng*Ago-FLAG could be co-precipitated with the purified recombinant His-tagged recA through Ni-NTA agarose. In addition, the purified recombinant His-tagged recA could also be co-precipitated with the purified r*Ng*Ago-FLAG through αFLAG M2 agarose (Figure [3C](#F3){ref-type="fig"}, D and [Supplementary Figure S18](#sup1){ref-type="supplementary-material"}). These indicated the direct interaction of *Ng*Ago with recA.

To further analyze the direct interaction of both proteins, the purified recombinant *Ng*Ago was covalently bound to the SPR sensor chip, and a concentration-dependent binding response was observed for the purified recombinant recA (*K*~a~ = 5.74 ± 0.23 × 10^3^ M^−1^ s^−1^, *K*~d~ = 2.4 ± 1.0 × 10^−4^ S^−1^, and *K*~D~ = 42.4 ± 20.3 nM) (Figure [3E](#F3){ref-type="fig"} and [F](#F3){ref-type="fig"}). Subsequently, the purified recombinant recA was covalently bound to the SPR sensor chip, and a concentration-dependent binding response was also observed for the purified recombinant *Ng*Ago (*K*~a~ = 2.32 ± 0.17 × 10^4^ M^−1^ s^−1^, *k*~d~ = 7.07 ± 0.19 × 10^−4^ S^−1^, and *K*~D~ = 30.6 ± 3.2 nM) (Figure [3G](#F3){ref-type="fig"} and [H](#F3){ref-type="fig"}). These results further confirmed the direct interaction of both proteins.

It is known that the efficiency of homologous sequence-mediated recombination was dependent on the interaction of recA with the target sequences. We further confirmed that *Ng*Ago could enhance interaction of recA with the target sequences, which was exhibited by Chip-qPCR (Figure [3I](#F3){ref-type="fig"}, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). As a result, the enhanced interaction of recA with the target sequences may account for *Ng*Ago-promoted gene editing through homologous recombination.

*Ng*Ago-assisted gene editing through enhancing recA-mediated DNA strand exchange {#SEC3-5}
---------------------------------------------------------------------------------

The recA promotes the central steps of recombination: it binds to single-stranded DNA (ssDNA) in an ATP-dependent manner, aligns and pairs two DNA molecules, and then promoting a strand switch followed by branch migration ([@B22],[@B41],[@B42]). The present study indicates *Ng*Ago-assisted gene editing through binding to recA, we conceived *Ng*Ago probably promotes recA-mediated DNA strand exchange, a major experimental model for the recombination activities ([@B41]). Interestingly, the purified recombinant *Ng*Ago indeed promoted recA-mediated DNA strand exchange in a concentration-dependent manner (Figure [3J](#F3){ref-type="fig"}), while it did not significantly promote the interaction of recA with ssDNA ([Supplementary Figure S19](#sup1){ref-type="supplementary-material"}). Therefore, the present study indicated that *Ng*Ago-assisted gene editing is through enhancing recA-mediated DNA strand exchange.

The PIWI-like domain of *Ng*Ago is required to enhance gene editing in bacteria {#SEC3-6}
-------------------------------------------------------------------------------

To functionally characterize the responsible domain of *Ng*Ago for enhancement of gene editing, we constructed four *Ng*Ago fragments to generate the pSHK5(TS)-*Ng*Ago A (1-267 aa, containing N domain), B (268--887 aa, containing PAZ, MID and PIWI domains), C (1--416 aa, containing N and PAZ domains) and D (417-887 aa, containing MID and PIWI domains) plasmids (Figure [4A](#F4){ref-type="fig"}, [Supplementary Table S1-S2](#sup1){ref-type="supplementary-material"}). The pSHK5(TS)-*Ng*Ago (A, B, C and D)-lyiLR plasmids were individually electro-transformed into *P. multocida*. As a result, isogenic mutants could only be detected with transformed *Ng*Ago B and D rather than A and C (Figure [4B](#F4){ref-type="fig"} and [Supplementary Figure S20](#sup1){ref-type="supplementary-material"}), indicating that the *Ng*Ago D fragment is enough to enhance gene editing in bacteria. Amino acid sequence alignment demonstrated that the *Ng*Ago D fragment (C-terminus of NgAgo) contains the MID and PIWI domains. The MID domain usually forms binding pockets that facilitate the anchoring of the 5′-phosphate of the oligonucleotide guide, while the PIWI domain of catalytically active Agos mediates target-strand cleavage ([@B28],[@B30]). Here, the C-terminus of *Ng*Ago is as efficient as full-length *Ng*Ago in enhancement of gene editing in bacteria, with almost 100% efficiency. Interestingly, using pull-down approaches coupled with LC-MS/MS, recA was identified from full-length of *Ng*Ago, and *Ng*Ago fragments B and D, but not from *Ng*Ago A fragment with the highest MASCOT search score and the largest numbers of identified unique peptides ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). The interaction between the C-terminus of *Ng*Ago and recA was further confirmed by forward/reverse protein-interaction assay (Figure [4C](#F4){ref-type="fig"}-[D](#F4){ref-type="fig"}). Thus, we conclude that the C-terminus of *Ng*Ago is responsible for gene editing in bacteria by interaction with recA.

![The PIWI-like domain of *Ng*Ago is required for promotion of gene editing in bacteria. (**A**) The structural homology modelling of *Ng*Ago major domains aligned to *Aquifex aeolicus* Argonaute (PDB: 1YVU) and *Thermus thermophilus* Argonaute (PDB: 5XOU) using the HHPred server and Pymol. N, L, PAZ, MID and PIWI domains are highlighted in purple, grey, blue, green and orange, respectively. The structure of other pAgos were supplied in Figure S11. (**B**) Comparison of the construction efficiency for the isogenic *lyi* mutant in the *P. multocida* strain GX-PM based on various *Ng*Ago fragments: A ([@B1]-267), B (268-887), C (1--416) and D (417--887). (**C**) Co-IP assay detection of interaction between recA and the various *Ng*Ago fragments with αFLAG agarose. The *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago (A, B or D)-Flag-asteL or pSHK5(TS)-asteL and cultured for 48 h. Total proteins were extracted for Co-IP assay with αFLAG agarose. (**D**) Co-IP assay detection of interaction between recA and the various *Ng*Ago fragments with SPA/G agarose and αrecA. The *E. coli* strain was transformed with pSHK5(TS)-*Ng*Ago (A, B or D)-Flag-asteL or pSHK5(TS)-asteL and cultured for 48 h. Total proteins were extracted for Co-IP assay with SPA/G agarose and αrecA. (**E**) Co-IP assay detection of interaction between recA and the MID domain (fragment E) or PIWI-like domain (fragment F) of *Ng*Ago with αFLAG agarose. The fragment D of *Ng*Ago and the vector were severed as the positive and negative controls. (**F**) Co-IP assay detection of interaction between recA and the MID domain (fragment E) or PIWI-like domain (fragment F) of *Ng*Ago with SPA/G agarose and αrecA. The fragment D of *Ng*Ago and the vector were severed as the positive and negative controls.](gkz040fig4){#F4}

To further elucidate whether the effect relies on MID and / or PIWI domain, pSHK5(TS)--*Ng*Ago E (417--650 aa, containing MID domain) and F (650--887 aa, containing PIWI-like domain) -opaLR plasmids were individually electro-transformed into *P. multocida*. As a result, isogenic mutants could be detected with transformed *Ng*Ago E and F with efficiency of 20% and 100% ([Supplementary Figure S21](#sup1){ref-type="supplementary-material"}), indicating that the PIWI-like domain is enough to enhance gene editing in bacteria. The interaction between the PIWI-like domain of *Ng*Ago and recA was further confirmed by forward/reverse protein-interaction assay (Figure [4E](#F4){ref-type="fig"} and [F](#F4){ref-type="fig"}). Thus, we conclude that the PIWI-like domain of *Ng*Ago is responsible for gene editing in bacteria by interaction with recA.

The pAgos enhance gene editing in bacteria {#SEC3-7}
------------------------------------------

*Ng*Ago enhances homologous sequence-guided gene editing in bacteria, which promoted us to further evaluate the effect of other pAgos. Interestingly, the isogenic *opa* gene mutants could easily be detected at 100% efficiency with *Pf*Ago-D, *Tt*Ago-D and *Aa*Ago-D, while the isogenic mutant based on the natural homologous recombination in the *P. multocida* strain was still not detected ([Supplementary Figure S22](#sup1){ref-type="supplementary-material"}). It indicated that enhancement of gene editing in bacteria was not solely for *Ng*Ago, and it might be mediated by other pAgos. Furthermore, the interactions of these pAgos with recA were also detected ([Supplementary Figure S23](#sup1){ref-type="supplementary-material"}), suggesting that these pAgos enhance gene editing in bacteria in a similar manner by which *Ng*Ago takes effect.

DISCUSSION {#SEC4}
==========

The development of a broad and effective genetic manipulation system is the fundamental for vaccine development or the study of pathogenesis. The developed *Ng*Ago-based system was highly efficient for gene editing in various bacterial strains. More importantly, this tool makes the rapid construction of an avirulent strain feasible. For example, the virulence of the constructed isogenic *hyae* mutant in the highly pathogenic *P. multocida* strain was significantly decreased (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}), potentiating the construction of a novel generation of avirulent vaccine strain with gene editing for fowl cholera. Additionally, the successful insertion of a *vp60* gene from *rabbit haemorrhagic disease virus* into the rabbit *P. multocida* strain provided an alternative strategy to construct a novel vaccine strain against two important infectious diseases in rabbit (Figure [1F](#F1){ref-type="fig"}). This was essential for developing a safe and cheap vaccine against *rabbit haemorrhagic disease virus* due to a lack of choices in addition to an inactivated vaccine derived from a clarified liver suspension from experimentally infected rabbits ([@B43]).

Argonaute proteins in eukaryotes and prokaryotes are evolutionarily conserved ([@B44]). The eukaryotic Argonaute proteins play a key role in RNA interference pathways either directly by binding and cleavage of the target RNA, or indirectly by binding to the target RNA followed by the recruitment of the silencing proteins ([@B44]). In contrast, several pAgos were reported to mediate nucleic acid-guided cleavage of cognate DNA targets ([@B31]) or RNA targets *in vitro* ([@B32],[@B35]). The present study identified a new way for the PIWI-like domain of some pAgos in enhancing homologous sequence-guided gene editing in bacteria independent of its potential enzymatic activity and a guide DNA or RNA. This will undoubtedly strengthen our understanding of the applications potential of pAgos on gene editing.

The recently developed CRISPR/Cas9 system is clearly a powerful tool for bacterial genome editing ([@B1],[@B17],[@B47]) that relies on gRNA:Cas9-directed cleavage at a targeted genomic site to kill unmutated cells and circumvent the need for selectable markers or counter-selection systems ([@B18]). The effect depends on cleavage by Cas9 with a guided RNA, meaning that the efficiency can change with different guide RNA sequences ([@B50]) and in different bacterial species; for example, it is ∼100% in *S. pneumonia* but only 65% in *E. coli* ([@B18]). Although a few improved CRISPR/Cas9 systems have been developed to prevent the off-target effects ([@B51],[@B52]), their application in bacteria has not been evaluated to date. More importantly, the CRISPR/Cas9 system requires a large gene (the gene length of Cas9 is ∼ 4 kb) and elements expressing a guide RNA, which increase the load of the tool vector. Thus, it will be difficult to introduce this system into some bacteria with unknown genetic background or lack of genetic technique (e.g. *P. multocida*) for gene editing.

In contrast, the pAgos system is completely distinct from CRISPR-Cas systems. Apart from its high efficiency for bacterial gene editing, this pAgos system has other additional merits. The PIWI-like domain of *Ng*Ago was only ∼0.7 kb, which makes the system easy to manipulate in only one vector to accomplish recombination at a high efficiency. Additionally, this system is independent of its potential nuclease activity, which could eliminate the concern for potential off-target damage to the genome (Figure [1C](#F1){ref-type="fig"}). In light of the PIWI-like domain of pAgos-assisted gene editing through the promotion of homologous recombination in bacteria, which was different from the currently developed tool to isolate mutants by killing non-mutant strains, like in the CRISPR-Cas system, the pAgos system could not only be considered an alternative system, but might also be a component in combination with other tools (e.g. CRISPR-Cas system) to further enhance the efficiency of gene editing.

While a DNA-guided *Ng*Ago system is controversial in its application in eukaryotic cells ([@B36],[@B38],[@B53]), based on the above findings, we conclude that the PIWI-like domain of *Ng*Ago system substantially enhances homologous recombination in bacteria through binding to recA to enhance recA-mediated DNA strand exchange, a major experimental model for the recombination activities ([@B41]). As the pAgos system only requires homologous arms and enhances homologous recombination without detectable off-target effects (genome damage), it offers great convenience for gene editing in bacteria, though the role of this system in mammal genome manipulation remains to be further elucidated. The present study also demonstrated a novel aspect of pAgos on gene editing in bacteria.
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More additional materials and methods are provided in the Supplemental materials and methods.
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